Ostenil 70 (Alendronate Sodium Monohydrate)

Alendronate sodium monohydrate, the active ingredient in Ostenil 70, is a bisphosphonate presented as a tablet for oral use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fracture. GNH USA supplies Ostenil 70 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ostenil 70 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ostenil 70 is a bisphosphonate that acts on bone metabolism to improve skeletal strength.

- Osteoporosis: reduces the risk of vertebral and hip fractures in post‑menopausal women and men. - Paget’s disease of bone: normalises abnormal bone turnover and alleviates bone pain. - Secondary osteoporosis: helps maintain bone density in patients receiving long‑term glucocorticoid therapy.

Adverse reactions to alendronate are reported across a spectrum of frequency.

Common Side Effects: - Upper gastrointestinal irritation: dyspepsia, heartburn or abdominal discomfort. - Musculoskeletal pain: transient bone, joint or muscle aches. - Nausea or vomiting. - Constipation or diarrhoea. - Headache. - Skin rash.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the maxillofacial region. - Atypical femoral fracture: low‑energy fracture of the subtrochanteric or diaphyseal femur. - Severe esophagitis or oesophageal ulceration. - Acute phase reaction: fever, myalgia and flu‑like symptoms. - Hypocalcaemia: low serum calcium levels, especially in patients with vitamin D deficiency. - Severe allergic reaction: anaphylaxis or angioedema.

Before initiating therapy, clinicians should evaluate patient history and baseline labs.

- Renal function: assess creatinine clearance; avoid in severe renal impairment. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk. - Gastro‑intestinal disorders: avoid in patients with active oesophageal disease. - Concomitant medications: review for drugs that may irritate the oesophagus or affect absorption. - Pregnancy and lactation: contraindicated; advise effective contraception. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Alendronate may interact with several medicines that influence absorption or bone metabolism.

Major Interactions (Avoid): - Calcium‑containing antacids or supplements: taken within 30 min of alendronate reduces its absorption. - Proton pump inhibitors (e.g., omeprazole): may diminish bioavailability when used chronically. - Intravenous bisphosphonates: concurrent use increases risk of ONJ and atypical fractures.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation. - Corticosteroids: additive risk of bone loss and gastrointestinal side effects. - Loop diuretics: can exacerbate hypocalcaemia if calcium intake is insufficient.